Pathophysiology
Research indicates that BB0238 and BB0323 interactions are essential for long-term spirochete persistence and transmission between ticks and mammals, suggesting a novel target for understanding and treating disseminated Lyme disease (PMID: 41481600).
The geographic distribution of Borrelia species varies significantly across regions, potentially affecting the accuracy of laboratory diagnostic tests (PMID: 39436129).
The antigenic profile of Borrelia burgdorferi sensu lato varies significantly based on plasmid content, leading to diverse pathogenicity and virulence among different isolates (PMID: 39338958).
The study by Hart et al. (2018) reveals that CspA (CRASP-1) expressed by Lyme borreliae binds to factor H and inhibits complement activation pathways, facilitating survival and transmission from feeding ticks to humans (PMID: 29813137). This mechanism contributes significantly to the pathophysiology of disseminated Lyme borreliosis by protecting spirochetes from complement-mediated killing.
Molecular studies in Serbia have identified several Borrelia species, with B. afzelii dominating at 75% followed by B. burgdorferi sensu stricto at 22.2%, highlighting the clinical variability linked to strain diversity (Cekanac et al., 2010; PMID: 26413064).
A study using yeast surface display (YSD) screening identified a tick gut protein with fibronectin type III domains that aids in the congregation of Borrelia burgdorferi within the tick gut during transmission, suggesting a critical role in the pathogen's migration towards salivary glands and subsequent host transmission (PMID: 25102051).
The study by Lazarus JJ et al. (2012) highlights that B. burgdorferi's ability to induce robust immune responses, including antibody production against lipoproteins and upregulation of immune mediators like TLR2 and MyD88, complicates the differentiation between active infection and early clearance using ELISA and PCR alone. [PMID: 22110528]
Studies have shown that decorin-binding proteins A (DbpA) and B (DbpB) are critical for the overall virulence of Borrelia burgdorferi, as evidenced by their roles in enhancing interactions with decorin and glycosaminoglycan, which significantly affect the infectious dose (ID50) and dissemination in murine models (Shi et al., 2008).
Epidemiology
Research indicates that hygromycin A can disrupt the transmission of Borrelia burgdorferi from Peromyscus leucopus to ticks, suggesting a potential epidemiological impact on reducing human Lyme disease incidence through reservoir targeting (PMID: 40614169).
The study highlights that despite anecdotal evidence and reported cases suggesting a significant public health issue, the actual number of tick-borne diseases (TBDs) in Australia remains unclear due to inadequate surveillance programs, exemplified by the Australian Senate inquiry noting the lack of clinical utility in the current diagnostic pathway ('Debilitating Symptom Complexes Attributed to Ticks' or DSCATT) [PMID: 41471236].
In Turkey, despite the presence of tick species capable of transmitting Lyme disease, only approximately 60 cases had been reported by 2010, totaling less than 100 cases overall, indicating it does not pose a significant health issue in the country (PMID: 39533171).
Wang et al. (2024) predict a significant rise in new cases of Lyme borreliosis globally, estimating 476,000 cases annually in the United States and between 128,000 to 200,000 in Western Europe, underscoring the increasing burden of the disease despite potential underestimation (PMID: 39436129).
In Europe, the Borrelia burgdorferi s.l. complex exhibits greater heterogeneity compared to North America, where B. burgdorferi sensu stricto predominates, influencing the clinical manifestations and necessitating tailored diagnostic strategies [PMID: 39375250].
Epidemiological data indicate that in Europe, B. afzelii, B. burgdorferi sensu stricto, and B. garinii are the primary genospecies causing Lyme disease infections, contrasting with North America where B. burgdorferi sensu stricto predominates with occasional B. mayonii infections (PMID: 39338958).
Clinical Presentation
A study involving 201 children in the United States showed that erythema migrans was present in 89% of cases, with arthritis, facial palsy, aseptic meningitis, and carditis occurring in significantly fewer percentages (7%, 3%, 1%, and 0.5% respectively) (PMID: 39533171).
Despite presenting without clinical signs of Lyme disease, a significant proportion of asymptomatic children in endemic regions tested positive for Borrelia antibodies via two-tiered serology, suggesting subclinical infections may still be present (PMID: 30067595).
Patients coinfected with Borrelia burgdorferi, Anaplasma phagocytophilum, and Babesia microti typically exhibit more severe clinical presentations than those infected with a single pathogen, likely due to immune system alterations caused by the parasites [PMID: 24359556].
In the study, patients with multiple skin lesions exhibited significantly higher rates of seropositivity across different serologic tests compared to those with single lesions (P < 0.001). This finding highlights the clinical significance of lesion multiplicity in antibody detection (PMID: 18716009).
The study indicates that the pepC10 ELISA captures IgM reactivity in erythema migrans patients more effectively, aiding in the early diagnosis and potential timely intervention for Lyme borreliosis (PMID: 9817857).
The research indicates that distinct strains of Borrelia burgdorferi can cause separate episodes of erythema migrans in the same individual, highlighting the complexity in clinical presentation (PMID: 9542928).
Among patients presenting with facial palsy after erythema chronicum migrans, neither IFA nor capture ELISA detected specific intrathecal antibodies, indicating that clinical symptoms alone may warrant further diagnostic investigation beyond serological tests (PMID: 7929776).
Although the paper focuses on diagnostic methods rather than clinical presentations, it highlights the diagnostic challenges in differentiating Lyme disease from other immune-mediated conditions in dogs, implying broader clinical considerations (Lindenmayer et al., 1990; PMID: 2405018).
Since Lyme disease symptoms are typically non-specific in early stages, Hyde et al.'s (1989) findings on detecting Borrelia burgdorferi antigens in urine could significantly aid clinicians in identifying patients sooner. [PMID: 2913036]
Diagnosis
The critical role of BB0238-BB0323 interactions in Borrelia persistence suggests that future diagnostic approaches might consider these protein interactions as indicators of ongoing infection (PMID: 41481600).
The research underscores the need for evaluating broader diagnostic tools such as multiplex serological assays to address diagnostic uncertainty in Lyme-like diseases in Australia, given the limitations of current diagnostic methods [PMID: 41471236].
Nayak A et al. (2025) utilized a whole-proteome microarray comprising 1,296 Borrelia afzelii proteins to identify novel antigenic targets for serodiagnosis, aiming to address the limitations of current diagnostic methods such as low sensitivity in early infection detection seen with standard two-tiered testing (STTT) and modified two-tiered testing (MTTT). This approach seeks to minimize false negatives, crucial for early intervention. [PMID: 40315844]
The study by Nayak A et al. (2025) underscores the limitations of existing diagnostic protocols like STTT and MTTT, noting that sensitivity in early infection stages remains suboptimal (as low as 14% for STTT in EM cases) and specificity is affected by asymptomatic infections and high background seroprevalence. [PMID: 40315844]
The study by Nayak A et al. (2025) indicates that their microarray approach could streamline diagnostic processes by offering a more objective method compared to the current subjective confirmatory western blot used in STTT and MTTT, potentially enhancing both speed and accuracy in diagnosing Lyme disease. [PMID: 40315844]
This retrospective study analyzed Lyme serology results from pediatric patients to assess test utilization patterns and outcomes, highlighting the importance of serological testing in diagnosing Lyme disease despite varying endemic levels (PMID: 39533171).
Lyme borreliosis symptoms frequently overlap with other conditions, making early diagnosis challenging without laboratory support, especially in cases where erythema migrans is absent (PMID: 39436129).
Clinical guidelines advise against using serological tests exclusively during the erythema migrans phase due to their poor performance in the early stages when antibody levels are not yet detectable (PMID: 39436129).
A study evaluated different testing strategies for diagnosing Lyme borreliosis in a European setting, finding that MTTT using two commercially available EIAs showed improved sensitivity compared to STTT, making it a potentially more effective approach despite the higher costs and labor intensity associated with immunoblots tailored for European genotypes [PMID: 39375250].
In Europe, where the Borrelia burgdorferi s.l. population is more diverse, immunoblots requiring genotype-specific recombinant antigens enhance specificity but increase costs and interpretive challenges compared to B. burgdorferi s.s.-specific Western blots used predominantly in North America [PMID: 39375250].
The study highlights that despite advancements in diagnostic techniques, the two-tiered serology assay, initially using ELISA followed by Western blot testing if results are positive or equivocal, remains the recommended primary diagnostic method for Lyme disease (PMID: 39338958).
Blood samples are not ideal for diagnosing Lyme disease because Borrelia burgdorferi sensu lato, except for B. mayonii, exists in low concentrations within the bloodstream, limiting their diagnostic utility (PMID: 39338958).
Differential Diagnosis
Given the identification of Borrelia burgdorferi sensu lato in Australian patients and ticks, alongside symptoms consistent with Lyme borreliosis, clinicians should consider LB alongside differential diagnoses such as aseptic meningitis, Bell’s palsy, peripheral neuropathy, multiple sclerosis, arthritis, and arbovirus infections like epidemic polyarthritis [PMID: 41471236].
Given the varied manifestations of Lyme disease, including skin, nervous system, and joint involvement, clinicians often utilize Lyme serology to aid in differential diagnosis, especially in non-endemic regions where alternative diagnoses must be carefully considered (PMID: 39533171).
While clinical signs attributed to Borrelia burgdorferi infection in horses may suggest Lyme borreliosis, serological confirmation alone does not definitively diagnose the condition, necessitating additional diagnostic steps (PMID: 32385952).
The study revealed that assay sensitivity increased when the IR6 peptide was derived from the infecting genospecies, indicating that accounting for genospecies diversity can enhance differential diagnosis accuracy in cases where erythema migrans is absent (Gomes-Solecki MJ et al., 2007; PMID: 17538122).
ELISA tests using recombinant Borrelia burgdorferi antigens demonstrated high specificity (97%) in differentiating Lyme borreliosis from other tick-borne diseases like Leptospira interrogans and Brucella sp. in cattle (PMID: 15368740).
While the C6 ELISA shows promise with high sensitivity, clinical judgment is still vital due to identified false positives in confirmed cases, aiding in accurate differential diagnosis (PMID: 15358654).
Given the detection of Borrelia burgdorferi sensu stricto antibodies in zoo animals, clinicians should consider Lyme borreliosis in their differential diagnosis for animals showing clinical signs suggestive of the disease, particularly those with a history of tick exposure (PMID: 14596540).
Management
Recent studies identified BB0238-BB0323 protein interactions as critical for Borrelia burgdorferi persistence and transmission. Utilizing X-ray crystallography and high-throughput screens, inhibitors targeting this interaction were discovered, with lomibuvir showing promise in reducing spirochete infectivity in murine models (PMID: 41481600).
A study involving Peromyscus leucopus, a primary reservoir for Borrelia burgdorferi in the eastern US, demonstrated that hygromycin A, when administered via baits, effectively disrupts the transmission cycle from rodents to ticks (PMID: 40614169).
The lack of progress in surveillance and diagnostic capability in Australia contributes to underrecognition of tick-borne diseases, emphasizing the need for improved diagnostics to enhance effective management [PMID: 41471236].
The research by Nayak A et al. (2025) suggests that identifying new Borrelia antigens could help distinguish between active and resolved infections, addressing a significant gap in current diagnostic approaches where persistence of antibodies complicates patient follow-up and management post-treatment. [PMID: 40315844]
Early diagnosis and prompt treatment are essential to prevent further progression of Lyme borreliosis and mitigate the risk of persistent symptoms (PMID: 39436129).
Despite advancements in serological testing strategies such as STTT and MTTT, there remains no definitive method to differentiate between active and past infections or quantify treatment efficacy in Lyme borreliosis [PMID: 39375250].
The study indicates that IFN-γ levels often decrease significantly after appropriate antibiotic therapy, suggesting that monitoring these levels could provide insights into treatment efficacy for patients with disseminated Lyme borreliosis. [PMID:34043758]
False positives in serological tests for Borrelia burgdorferi can lead to unnecessary antimicrobial therapy in horses, which not only wastes resources but also increases the risk of adverse effects from prolonged antibiotic use (PMID: 32385952).
Enhanced diagnostic sensitivity through methods like digital PCR could facilitate earlier intervention with antibiotics, potentially reducing long-term morbidity associated with Lyme disease (PMID: 33253179).
Given the high diagnostic accuracy of CXCL13 ELISA and LFA for Lyme neuroborreliosis (PMID: 32434781), these assays can facilitate timely and accurate diagnosis, thereby supporting evidence-based treatment decisions in clinical practice.
The shift towards EIA-based testing methodologies highlighted by Mead et al. (PMID: 31415492) can streamline the diagnostic process, potentially leading to more rapid initiation of appropriate management strategies for Lyme disease patients.
To address the potential role of horses as reservoirs for Lyme borreliosis in Jeju, it is recommended that seroprevalence testing be conducted on horses to identify carriers and implement appropriate management strategies. (PMID: 30071709)
Targeting the complement evasion mechanisms mediated by CspA could lead to novel therapeutic approaches for managing disseminated Lyme borreliosis by enhancing host immune responses against spirochetes (PMID: 29813137).
The adoption of a two-tier testing algorithm utilizing C6 peptide EIAs as the second tier shows equivalent specificity to conventional methods while mitigating drawbacks like subjectivity and logistical constraints associated with immunoblot assays (PMID: 29550060).
Given the diagnostic shortcomings highlighted in the study, there is an urgent need for better diagnostic assays to accurately identify active Lyme neuroborreliosis cases, thereby facilitating timely antibiotic treatment (PMID: 29367297).
Although focused on diagnosis, the improved sensitivity of the T2MR assay could lead to earlier detection of Borrelia infections, potentially enabling more timely initiation of appropriate treatment strategies [PMID: 28566314].
Given the comparable diagnostic sensitivity of the C6 EIA to traditional 2-tiered testing, its application in pediatric settings could potentially expedite diagnosis processes, though immunoblots are still crucial for specificity assurance. (PMID: 27358358)
Identification of tick gut proteins that facilitate Borrelia burgdorferi congregation within the gut suggests potential avenues for developing new interventions aimed at disrupting transmission pathways (PMID: 25102051).
Complications
Some patients with Lyme borreliosis develop chronic symptoms like arthritis that do not fully resolve with antibiotic therapy alone, suggesting potential long-term complications (Hytönen et al., 2008).
Perticarari et al. (2003) found that Borrelia burgdorferi induces apoptosis in lymphocytes, potentially leading to immune dysregulation and complicating the clinical course of disseminated Lyme borreliosis [PMID: 12946326].
In murine models of Lyme disease, the persistence of Borrelia burgdorferi led to detectable levels of proinflammatory cytokines (IL-1, TNF-alpha, IL-12) even during resolving disease phases, indicating ongoing inflammatory processes that could relate to chronic complications observed in disseminated Lyme borreliosis (Montgomery RR et al., 2001; PMID: 11343212).
Prognosis & Follow-up
Given that this protein complex is vital for Borrelia persistence, its modulation could influence treatment outcomes and patient prognosis in disseminated Lyme disease (PMID: 41481600).
By enhancing diagnostic accuracy with novel Borrelia antigens identified via whole-proteome microarray, Nayak A et al. (2025) propose a pathway towards more precise prognosis and follow-up protocols, potentially improving patient outcomes by enabling earlier detection and intervention. [PMID: 40315844]
Results showed a notable decline in IFN-γ levels 6 weeks (P = .007) and 6 months (P = .001) post-treatment, indicating that regular monitoring of IFN-γ response could be beneficial for prognosis and follow-up strategies. [PMID:34043758]
The robust diagnostic performance of CXCL13 assays (PMID: 32434781) ensures accurate identification of Lyme neuroborreliosis cases, which is foundational for effective monitoring and follow-up care tailored to individual patient needs.
The case of a Jeju resident diagnosed with Lyme borreliosis highlights the importance of timely diagnosis and treatment to mitigate potential complications, particularly for high-risk groups such as horse industry workers. (PMID: 30071709)
The ability of Lyme borreliae to evade complement via CspA could contribute to more severe or disseminated disease courses, suggesting that monitoring complement evasion mechanisms may aid in predicting prognosis and guiding long-term follow-up care (PMID: 29813137).
Although the study emphasizes diagnostic performance, efficient diagnosis through the C6 EIA could facilitate timely intervention and subsequent follow-up care, potentially impacting patient outcomes positively. (PMID: 27358358)
The research by Lazarus JJ et al. (2012) suggests that combining ELISA antibody assessments with PCR detection of B. burgdorferi DNA could offer improved prognostic markers for Lyme disease patients, facilitating more accurate follow-up care and treatment outcome evaluations. [PMID: 22110528]
Special Populations
This study highlights that zoo animals, encompassing various species such as ungulates and carnivores, exhibit a significant seroprevalence of Borrelia burgdorferi sensu stricto, underscoring the need for targeted surveillance and preventive measures against Lyme borreliosis (PMID: 14596540).
Among blood donors in Kalmar County, Sweden, elderly men (60-70 years old) showed significantly higher seroprevalence rates (46% in 2011, 52% in 2014) compared to other age groups, highlighting the need for tailored diagnostic approaches in this demographic (PMID: 28225145).
The study (PMID: 26961275) indicated that the seroprevalence of Borrelia burgdorferi IgG antibodies increased significantly with age, which could imply higher exposure risks or persistent antibody presence in older age groups affected by Lyme borreliosis.
Given the elevated seroprevalence of Borrelia burgdorferi in dogs from Cotia County, regions with comparable ecological and environmental factors should consider heightened surveillance and preventive measures for Lyme disease in humans. (PMID: 11696846)
The study by Sugiyama et al. (1998) identifies wild Japanese serows as significant reservoirs of Lyme borreliosis, suggesting these animals may contribute to human infection risks in specific geographic areas of Japan (PMID: 9673949).
In Taiwan, syphilis patients showed markedly higher seropositivity rates for Borrelia burgdorferi (58%) compared to healthy individuals (3%), underscoring the diagnostic complexities in populations with concurrent syphilis (Huang et al., 1994; PMID: 9747351).
Barron County, an area with endemic human Lyme disease, showed significantly higher seropositivity in dairy cattle (17%) compared to statewide average (7%), indicating potential utility of livestock as indicators of human infection risk (PMID: 7802388).
Key Recommendations
Given the efficacy of hygromycin A in clearing Borrelia burgdorferi from Peromyscus leucopus, recommending the use of hygromycin A baits could be a strategic recommendation for reducing Lyme disease risk (PMID: 40614169). (Evidence: Moderate)
Given the reliable detection of IFN-γ and its significant decrease post-treatment, integrating QuantiFERON ELISA into clinical practice could enhance the assessment of treatment efficacy and patient management. [PMID:34043758] (Evidence: Strong)
Based on findings that modified two-tier testing (MTTT) demonstrates enhanced sensitivity for early Lyme disease diagnosis in European sera, it is recommended to explore and potentially adopt MTTT algorithms incorporating tailored EIAs for better clinical diagnostic accuracy, especially in atypical presentations. [PMID: 32632699] (Evidence: Strong)
Based on the findings from Mead et al. (PMID: 31415492), clinicians and laboratories are advised to incorporate FDA-cleared serologic assays that employ an EIA as the second test in a two-test format for diagnosing Lyme disease, adhering to the performance standards set forth since the 1994 Second National Conference on Serologic Diagnosis of Lyme Disease. (Evidence: Strong)
Based on the findings from Weiner et al. (PMID: 26376927), it is recommended to explore the integration of these additional Borrelia burgdorferi antigens into existing diagnostic frameworks to enhance sensitivity in early Lyme disease detection. (Evidence: Strong)
Based on research by Wormser et al. (PMID: 24068010), it is recommended that diagnostic laboratories adopt the C6 ELISA as part of the two-tiered testing approach for Lyme disease to enhance cost-effectiveness without sacrificing diagnostic accuracy. (Evidence: Moderate)
The study demonstrates that monitoring C6 antibody levels quantitatively can effectively track treatment response in dogs with Lyme borreliosis, supporting its potential application in human clinical practice for assessing treatment outcomes (PMID: 18003819). (Evidence: Moderate)
Given the variability in ELISA sensitivity based on genospecies and panel composition, it is recommended that diagnostic protocols incorporate tailored serum panels reflective of local Borrelia genospecies prevalence to enhance diagnostic accuracy (Gomes-Solecki MJ et al., 2007; PMID: 17538122). (Evidence: Strong)
Given the strong correlation between decreased C6 antibody titers and successful treatment outcomes in culture-confirmed Lyme borreliosis cases, monitoring these titers can be recommended as part of follow-up care. [PMID: 16148173] (Evidence: Moderate)
References
1 Arnaboldi PM, D'Arco C, Hefter Y, Nolan S, Jobe DA, Callister SM et al.. Detection of IFN-γ Secretion in Blood Samples Collected Before and After Treatment of Varying Stages of Lyme Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021. link
1 papers cited of 201 indexed.